MIS BAIR

Study short name: MIS BAIR (Melbourne Infant Study: BCG for Allergy & Infection Reduction)

Study full name: A randomised, controlled trial to determine if BCG immunisation at birth prevents the development of allergy & infection in infants

Principle Investigator: Nigel Curtis

Administering Institute: Murdoch Children’s Research Institute

Major funding sources: National Health and Medical Research Council (NHMRC), Royal Children’s Hospital Foundation, University of Melbourne and Murdoch Children’s Research Institute

Study focus: Prevention

Study design: Intervention

Main study aim: To assess whether the BCG vaccine will prevent food allergy, eczema and lower respiratory tract infections in the first 5 years of life.

Additional study information: Study participants randomised to group 1 received a single 0.05 mL intradermal injection of BCG Vaccine SSI or BCG 10 Vaccine over the distal insertion of the deltoid muscle onto the humerus approximately one third down the upper left arm.

Study population: 1272 healthy newborns randomised in the first 10 days of life.

Study status: Recruitment completed September 2016. Data collection ongoing, through February 2022.

Study website: www.misbair.org.au

ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT01906853

Study contact: [email protected]

Last modified: April 9th 2019 | Date created: April 9th 2019

Last modified: April 9th 2019 | Date created: April 9th 2019